凝固市場規模・予測（2020年～2030年）、世界・地域シェア、動向、成長機会分析レポート収録範囲適応疾患別（ビタミンK欠乏症、肝疾患、播種性血管内凝固・肺塞栓症、循環性抗凝固薬の開発、血友病、フォンウィルブランド病、その他）、タイプ別（臨床検査分析装置（コントロール＆キャリブレーター、臨床検査分析装置（コントロール＆キャリブレーター、アッセイ＆試薬、装置／システム、凝固因子、その他）およびPOC検査分析装置]、提供サービス[診断（プロトロンビン時間検査、フィブリノーゲン検査、活性化凝固時間検査、活性化部分トロンボプラスチン時間検査、D-ダイマー検査、血小板機能検査、その他）、治療（抗線溶薬、避妊薬、デスモプレシンおよび免疫抑制薬、ビタミンKサプリメント、血液凝固阻止薬、トロンビン阻害薬または血栓溶解薬、補充療法、カテーテルによる血栓除去、その他）]、技術（光学技術、機械技術、電気化学技術、その他）、エンドユーザー（臨床検査室、病院、その他）、地域（北米、欧州、アジア太平洋、中南米、中東アフリカ）

Coagulation Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease Indications (Vitamin K Deficiency, Liver Disease, Disseminated Intravascular Coagulation & Pulmonary Embolism, Development of Circulating Anticoagulants, Hemophilia, Von Willebrand's Disease, and Others), Type [Clinical Laboratory Analyzers (Controls & Calibrators, Assays & Reagents, Instruments/Systems, Coagulation Factors, and Others) and Point-of-Care Testing Analyzers], Offering [Diagnosis (Prothrombin Time Testing, Fibrinogen Testing, Activated Clotting Time Testing, Activated Partial Thromboplastin Time Testing, D-Dimmer Testing, Platelets Function Testing, and Others) and Treatment (Anti-Fibrinolytic Drugs, Birth Control Pills, Desmopressin & Immunosuppressive Medicines, Vitamin K Supplements, Blood Thinners, Thrombin Inhibitors or Thrombolytics, Replacement Therapy, Catheter-Assisted Thrombus Removal, and Others)], Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, and Others), End User (Clinical Laboratories, Hospitals, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)

凝固市場は、2022年の62億9,500万米ドルから2030年には108億5,300万米ドルに成長すると予想され、2022年から2030年までの年平均成長率は7.0％を記録すると予測されている。生活習慣の変化と老年人口の増加は... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
The Insight Partners ザ・インサイトパートナーズ	2023年10月11日	US$4,550 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	250	英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

サマリー

凝固市場は、2022年の62億9,500万米ドルから2030年には108億5,300万米ドルに成長すると予想され、2022年から2030年までの年平均成長率は7.0％を記録すると予測されている。

生活習慣の変化と老年人口の増加は、血液疾患の有病率を高める主な要因のひとつである。そのため、早期診断と早期治療に対する需要が高まっている。主要企業は、患者集団の生活の質を高めるために、有機的・無機的なさまざまな戦略を通じて、いくつかの取り組みを行っている。

- 2020年7月、シスメックス株式会社は自動血液凝固分析装置CN-6500/CN-3500を日本で発売した。この分析装置は、血液凝固・血小板凝集パラメータ、血栓症・止血パラメータを測定する。

- 2020年4月、米国のHaemonetics Corporationは血液凝固診断システム開発会社のEnicorを買収した。

- 2021年10月、Trivitron HealthcareはインドのDiagon Ltdが製造する新しい凝固分析装置製品ラインを発売した。

- 2021年6月、トリビトロン・ヘルスケアは糖尿病、ヘモグロビン変動、サラセミアのモニタリングに役立つNANO H5とNANO H110を発表。

- 2021年2月、シーメンス・ヘルティニアーズとシスメックス・コーポレーションは、全世界における止血製品の供給、流通、販売、サービスに関する契約を更新した。この契約には複数年の延長も含まれている。さらに、シーメンス・ヘルスイニアーズ社は、シスメックス社のCN-3000やCN-6000などの自動血液凝固分析装置の販売にも合意した。

- 2022年7月、堀場メディカルは最新の止血分析装置「Yumizen G800」と「G1550」、および一般的な血液凝固検査に便利な即使用可能な試薬を発売した。この製品ラインナップの拡充により、HORIBA Medicalは、あらゆる規模や要件の検査室向けに、包括的な止血システムと高度な試薬のセレクションを提供することになった。

このように、主要市場プレーヤーによる有機的・無機的なさまざまな戦略の採用は、予測期間中、凝固市場成長の機会を提供すると期待される。

心血管疾患の有病率の上昇が凝固市場の成長を牽引

心疾患は、心房細動や脳卒中などの状態による入院、死亡、身体能力の低下の主な原因の1つである。心臓病は止血系、血管系、血液の流体力学に影響を及ぼし、動脈血栓症や静脈血栓症を引き起こす。血栓症は心血管系疾患による死亡および合併症の主な原因である。喫煙や高血圧によって損傷を受けた血管は、血管を覆うコレステロールを多く含むプラークを形成し、これが破裂して血小板が凝固することがある。凝固障害では、心筋梗塞、脳卒中、血管床でのアテローム血栓性イベントのリスクがある。心不全（HF）は心房細動（AF）の有無とは無関係に血栓塞栓症のリスク上昇に関係する。血小板の活性化や凝固系の異常は，心不全患者における重篤な血栓塞栓症のリスクを増大させる。

2022 Heart Disease & Stroke Statistical Update Fact Sheetによると、2020年には世界中でCVDによる死亡が1億1,910万人、脳卒中と虚血性脳卒中の症例がそれぞれ8,910万人と6,820万人記録されている。National Center for Chronic Disease Prevention and Health Promotionによると、2023年、米国では毎年877,500人が心臓病で死亡すると報告されている。米国心臓協会によると、2035年までに1億3,000万人以上のアメリカ人が何らかの形でCVDを発症する可能性がある。Global Burden of Disease Study 2019』によると、2019年のアジア太平洋地域の死因のトップはCVDで、1,080万人（死亡者全体の35％）を引き起こしている。

凝固検査は、心臓発作を引き起こす可能性のある血液凝固を予防するのに役立つ。凝固分析装置は、冠動脈バイパス手術や血管形成術の際に使用され、血液凝固状態に関する情報を監視する。このように、心血管疾患の罹患率の増加が凝固市場の成長を後押ししている。

凝固市場は、適応疾患、タイプ、提供、技術、エンドユーザー、地域によって区分される。適応疾患別では、凝固市場はビタミンK欠乏症、肝疾患、播種性血管内凝固・肺塞栓症、循環性抗凝固薬開発、血友病、von Willebrand病、その他に区分される。凝固市場はタイプ別に、臨床検査用分析装置とポイントオブケア検査用分析装置に区分される。臨床検査分析装置は、コントロール＆キャリブレーター、アッセイ＆試薬、機器／システム、凝固因子、その他で構成される。凝固市場は提供する製品によって診断と治療に区分される。診断セグメントはさらに、プロトロンビン時間検査、フィブリノゲン検査、活性化凝固時間検査、活性化部分トロンボプラスチン時間検査、Dダイマー検査、血小板機能検査、その他に分類される。治療分野はさらに、抗線溶薬、避妊薬、デスモプレシン＆免疫抑制薬、ビタミンKサプリメント、血液希釈薬、トロンビン阻害薬または血栓溶解薬、補充療法、カテーテル補助血栓除去、その他に分類される。技術別では、凝固市場は光学技術、機械技術、電気化学技術、その他に区分される。エンドユーザーに基づくと、凝固市場は臨床検査室、病院、その他に区分される。

地域別では、北米、欧州、アジア太平洋、中東・アフリカ、中南米に区分される。凝固市場で最大のシェアを占めるのは北米である。北米が大きな市場シェアを占めているのは、血液疾患の増加、心房細動（AFib）などの心血管系疾患の増加、新規および既存の製品開発に従事する大手市場プレイヤーの存在によるものである。北米の凝固市場は米国が最大のシェアを占めている。血液疾患患者の急増、心血管疾患の有病率の増加、血液疾患予防のための政府支援などが、予測期間中の北米凝固市場の成長を後押しすると予想される。カナダ予防医療タスクフォース（Canadian Task Force on Preventive Health Care）によると、カナダにおける心房細動の発症率は年間4.5%増加し、40歳以上の生涯リスクは25%に達する。約30万人のカナダ人が遺伝性の出血性疾患遺伝子を持っている。このうち10人に1人、少なくとも3万人のカナダ人が、医療を必要とするほど重篤な症状を持っている。その多くは適切な診断を受けていない。遺伝性出血性疾患のための包括的ケアクリニックのカナダのネットワークに登録されている遺伝性出血性疾患の患者はわずか10,000人である。カナダ血友病協会によると、〜30万人のカナダ人が遺伝性血液疾患の遺伝子を持っている。したがって、先天性血液疾患の症例数の増加は、カナダにおける凝固市場の成長と関連づけることができる。

米国心臓協会（AHA）、米国疾病予防管理センター（CDC）、欧州連合（EU）、カナダ予防医療タスクフォース（Canadian Task Force on Preventive Health Care）などは、凝固市場に関する報告書を作成する際に参照した主要な一次情報源および二次情報源である。

ページTOPに戻る

TABLE OF CONTENTS

1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Coagulation Market Landscape
4.1 Overview
4.2 PEST Analysis
5. Coagulation Market - Key Industry Dynamics
5.1 Key Market Drivers:
5.1.1 Market Drivers
5.1.2 Increasing Prevalence of Blood Disorders
5.1.3 Rising Prevalence of Cardiovascular Diseases
5.2 Market Restraints
5.2.1 High Costs Associated with Coagulation Analyzers
5.3 Market Opportunities
5.3.1 Growing Organic and Inorganic Strategies by Key Market Players
5.4 Future Trends
5.4.1 Development of Point-of-Care (POC) Coagulation Analyzers
5.5 Impact Analysis
6. Coagulation Market - Global Market Analysis
6.1 Coagulation Market Revenue (US$ million), 2022 – 2030
6.2 Geography Analysis Market Revenue (US$ million), 2022 – 2030
7. Global Coagulation Market – Revenue and Forecast to 2030 – by Disease Indication
7.1 Overview
7.2 Coagulation Market Revenue Share, by Disease Indication 2022 & 2030 (%)
7.3 Vitamin K Deficiency
7.3.1 Overview
7.3.2 Vitamin K Deficiency: Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Liver Disease
7.4.1 Overview
7.4.2 Liver Disease: Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Disseminated Intravascular Coagulation and Pulmonary Embolism
7.5.1 Overview
7.5.2 Disseminated Intravascular Coagulation and Pulmonary Embolism: Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Development of Circulating Anticoagulant
7.6.1 Overview
7.6.2 Development of Circulating Anticoagulant: Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Hemophilia
7.7.1 Overview
7.7.2 Hemophilia: Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
7.8 Von Willebrand's Disease
7.8.1 Overview
7.8.2 Von Willebrand's Disease: Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
7.9 Others
7.9.1 Overview
7.9.2 Others: Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
8. Global Coagulation Market – Revenue and Forecast to 2030 – by Type
8.1 Overview
8.2 Coagulation Market Revenue Share, by Type 2022 & 2030 (%)
8.3 Clinical Laboratory Analyzers
8.3.1 Overview
8.3.2 Clinical Laboratory Analyzers: Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
8.3.2.1 Global Coagulation Market, by Clinical Laboratory Analyzers
8.4 Point-of-Care Testing Analyzers
8.4.1 Overview
8.4.2 Point-of-Care Testing Analyzers: Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
9. Global Coagulation Market – Revenue and Forecast to 2030 – by Offering
9.1 Overview
9.2 Coagulation Market Revenue Share, by Offering 2022 & 2030 (%)
9.3 Diagnosis
9.3.1 Overview
9.3.2 Diagnosis: Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
9.3.2.1 Global Coagulation Market, by Diagnosis
9.4 Treatment
9.4.1 Overview
9.4.2 Treatment: Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
9.4.2.1 Global Coagulation Market, by Treatment
10. Global Coagulation Market – Revenue and Forecast to 2030 – by Technology
10.1 Overview
10.2 Coagulation Market Revenue Share, by Technology 2022 & 2030 (%)
10.3 Optical Technology
10.3.1 Overview
10.3.2 Optical Technology: Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
10.4 Mechanical Technology
10.4.1 Overview
10.4.2 Mechanical Technology: Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
10.5 Electrochemical Technology
10.5.1 Overview
10.5.2 Electrochemical Technology: Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
10.6 Others
10.6.1 Overview
10.6.2 Others: Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
11. Global Coagulation Market – Revenue and Forecast to 2030 – by End User
11.1 Overview
11.2 Coagulation Market Revenue Share, by End User 2022 & 2030 (%)
11.3 Clinical Laboratories
11.3.1 Overview
11.3.2 Clinical Laboratories: Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
11.4 Hospitals
11.4.1 Overview
11.4.2 Hospitals: Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
11.5 Others
11.5.1 Overview
11.5.2 Others: Coagulation Market – Revenue and Forecast to 2030 (US$ Million)
12. Coagulation Market - Geographical Analysis
12.1 North America Coagulation Market, Revenue And Forecast To 2030
12.1.1 Overview
12.1.2 North America Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.1.3 North America Coagulation Market, by Disease Indication
12.1.4 North America Coagulation Market, by Type
12.1.4.1 North America Coagulation Market, by Clinical Laboratory Analyzers
12.1.5 North America Coagulation Market, by Offering
12.1.5.1 North America Coagulation Market, by Diagnosis
12.1.5.2 North America Coagulation Market, by Treatment
12.1.6 North America Coagulation Market, by Technology
12.1.7 North America Coagulation Market, by End User
12.1.7.1 North America Coagulation Market, by Country
12.1.7.2 US
12.1.7.2.1 Overview
12.1.7.2.2 US Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.1.7.2.3 US Coagulation Market, by Disease Indication
12.1.7.2.4 US Coagulation Market, by Type
12.1.7.2.4.1 US Coagulation Market, by Clinical Laboratory Analyzers
12.1.7.2.5 US Coagulation Market, by Offering
12.1.7.2.5.1 US Coagulation Market, by Diagnosis
12.1.7.2.5.2 US Coagulation Market, by Treatment
12.1.7.2.6 US Coagulation Market, by Technology
12.1.7.2.7 US Coagulation Market, by End User
12.1.7.3 Canada
12.1.7.3.1 Overview
12.1.7.3.2 Canada Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.1.7.3.3 Canada Coagulation Market, by Disease Indication
12.1.7.3.4 Canada Coagulation Market, by Type
12.1.7.3.4.1 Canada Coagulation Market, by Clinical Laboratory Analyzers
12.1.7.3.5 Canada Coagulation Market, by Offering
12.1.7.3.5.1 Canada Coagulation Market, by Diagnosis
12.1.7.3.5.2 Canada Coagulation Market, by Treatment
12.1.7.3.6 Canada Coagulation Market, by Technology
12.1.7.3.7 Canada Coagulation Market, by End User
12.1.7.4 Mexico
12.1.7.4.1 Overview
12.1.7.4.2 Mexico Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.1.7.4.3 Mexico Coagulation Market, by Disease Indication
12.1.7.4.4 Mexico Coagulation Market, by Type
12.1.7.4.4.1 Mexico Coagulation Market, by Clinical Laboratory Analyzers
12.1.7.4.5 Mexico Coagulation Market, by Offering
12.1.7.4.5.1 Mexico Coagulation Market, by Diagnosis
12.1.7.4.5.2 US Coagulation Market, by Treatment
12.1.7.4.6 Mexico Coagulation Market, by Technology
12.1.7.4.7 Mexico Coagulation Market, by End User
12.2 Europe Coagulation Market, Revenue And Forecast to 2030
12.2.1 Overview
12.2.2 Europe Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.2.3 Europe Coagulation Market, by Disease Indication
12.2.4 Europe Coagulation Market, by Type
12.2.4.1 Europe Coagulation Market, by Clinical Laboratory Analyzers
12.2.5 Europe Coagulation Market, by Offering
12.2.5.1 Europe Coagulation Market, by Diagnosis
12.2.5.2 Europe Coagulation Market, by Treatment
12.2.6 Europe Coagulation Market, by Technology
12.2.7 Europe Coagulation Market, by End User
12.2.8 Europe Coagulation Market by Country
12.2.8.1 Germany
12.2.8.1.1 Overview
12.2.8.1.2 Germany Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.2.8.1.3 Germany Coagulation Market, by Disease Indication
12.2.8.1.4 Germany Coagulation Market, by Type
12.2.8.1.4.1 Germany Coagulation Market, by Clinical Laboratory Analyzers
12.2.8.1.5 Germany Coagulation Market, by Offering
12.2.8.1.5.1 Germany Coagulation Market, by Diagnosis
12.2.8.1.5.2 Germany Coagulation Market, by Treatment
12.2.8.1.6 Germany Coagulation Market, by Technology
12.2.8.1.7 Germany Coagulation Market, by End User
12.2.8.2 UK
12.2.8.2.1 Overview
12.2.8.2.1.1 UK Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.2.8.2.2 UK Coagulation Market, by Disease Indication
12.2.8.2.3 UK Coagulation Market, by Type
12.2.8.2.3.1 UK Coagulation Market, by Clinical Laboratory Analyzers
12.2.8.2.4 UK Coagulation Market, by Offering
12.2.8.2.4.1 UK Coagulation Market, by Diagnosis
12.2.8.2.4.2 UK Coagulation Market, by Treatment
12.2.8.2.5 UK Coagulation Market, by Technology
12.2.8.2.6 UK Coagulation Market, by End User
12.2.8.3 France
12.2.8.3.1 Overview
12.2.8.3.1.1 France Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.2.8.3.2 France Coagulation Market, by Disease Indication
12.2.8.3.3 France Coagulation Market, by Type
12.2.8.3.3.1 France Coagulation Market, by Clinical Laboratory Analyzers
12.2.8.3.4 France Coagulation Market, by Offering
12.2.8.3.4.1 France Coagulation Market, by Diagnosis
12.2.8.3.4.2 France Coagulation Market, by Treatment
12.2.8.3.5 France Coagulation Market, by Technology
12.2.8.3.6 France Coagulation Market, by End User
12.2.8.4 Italy
12.2.8.4.1 Overview
12.2.8.4.1.1 Italy Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.2.8.4.2 Italy Coagulation Market, by Disease Indication
12.2.8.4.3 Italy Coagulation Market, by Type
12.2.8.4.3.1 Italy Coagulation Market, by Clinical Laboratory Analyzers
12.2.8.4.4 Italy Coagulation Market, by Offering
12.2.8.4.4.1 Italy Coagulation Market, by Diagnosis
12.2.8.4.4.2 Italy Coagulation Market, by Treatment
12.2.8.4.5 Italy Coagulation Market, by Technology
12.2.8.4.6 Italy Coagulation Market, by End User
12.2.8.5 Spain
12.2.8.5.1 Overview
12.2.8.5.2 Spain Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.2.8.5.3 Spain Coagulation Market, by Disease Indication
12.2.8.5.4 Spain Coagulation Market, by Type
12.2.8.5.4.1 Spain Coagulation Market, by Clinical Laboratory Analyzers
12.2.8.5.5 Spain Coagulation Market, by Offering
12.2.8.5.5.1 Spain Coagulation Market, by Diagnosis
12.2.8.5.5.2 Spain Coagulation Market, by Treatment
12.2.8.5.6 Spain Coagulation Market, by Technology
12.2.8.5.7 Spain Coagulation Market, by End User
12.2.8.6 Rest of Europe
12.2.8.6.1 Overview
12.2.8.6.2 Rest of Europe Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.2.8.6.3 Rest of Europe Coagulation Market, by Disease Indication
12.2.8.6.4 Rest of Europe Coagulation Market, by Type
12.2.8.6.4.1 Rest of Europe Coagulation Market, by Clinical Laboratory Analyzers
12.2.8.6.5 Rest of Europe Coagulation Market, by Offering
12.2.8.6.5.1 Rest of Europe Coagulation Market, by Diagnosis
12.2.8.6.5.2 Rest of Europe Coagulation Market, by Treatment
12.2.8.6.6 Rest of Europe Coagulation Market, by Technology
12.2.8.6.7 Rest of Europe Coagulation Market, by End User
12.3 Asia Pacific Coagulation Market, Revenue and Forecast to 2030
12.3.1 Overview
12.3.2 Pacific Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.3.3 Asia Pacific Coagulation Market, by Disease Indication
12.3.4 Asia Pacific Coagulation Market, by Type
12.3.4.1 Asia Pacific Coagulation Market, by Clinical Laboratory Analyzer
12.3.5 Asia Pacific Coagulation Market, by Offering
12.3.5.1 Asia Pacific Coagulation Market, by Diagnosis
12.3.5.2 Asia Pacific Coagulation Market, by Treatment
12.3.6 Asia Pacific Coagulation Market, by Technology
12.3.7 Asia Pacific Coagulation Market, by End User
12.3.8 Asia Pacific Coagulation Market by Country
12.3.8.1 China
12.3.8.1.1 Overview
12.3.8.1.2 China Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.3.8.1.3 China Coagulation Market, by Disease Indication
12.3.8.1.4 China Coagulation Market, by Type
12.3.8.1.4.1 China Coagulation Market, by Clinical Laboratory Analyzer
12.3.8.1.5 China Coagulation Market, by Offering
12.3.8.1.5.1 China Coagulation Market, by Diagnosis
12.3.8.1.5.2 China Coagulation Market, by Treatment
12.3.8.1.6 China Coagulation Market, by Technology
12.3.8.1.7 China Coagulation Market, by End User
12.3.8.2 Japan
12.3.8.2.1 Overview
12.3.8.2.2 Japan Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.3.8.2.3 Japan Coagulation Market, by Disease Indication
12.3.8.2.4 Japan Coagulation Market, by Type
12.3.8.2.4.1 Japan Coagulation Market, by Clinical Laboratory Analyzer
12.3.8.2.5 Japan Coagulation Market, by Offering
12.3.8.2.5.1 Japan Coagulation Market, by Diagnosis
12.3.8.2.5.2 Japan Coagulation Market, by Treatment
12.3.8.2.6 Japan Coagulation Market, by Technology
12.3.8.2.7 Japan Coagulation Market, by End User
12.3.8.3 India
12.3.8.3.1 Overview
12.3.8.3.2 India Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.3.8.3.3 India Coagulation Market, by Disease Indication
12.3.8.3.4 India Coagulation Market, by Type
12.3.8.3.4.1 India Coagulation Market, by Clinical Laboratory Analyzer
12.3.8.3.5 India Coagulation Market, by Offering
12.3.8.3.5.1 India Coagulation Market, by Diagnosis
12.3.8.3.5.2 India Coagulation Market, by Treatment
12.3.8.3.6 India Coagulation Market, by Technology
12.3.8.3.7 India Coagulation Market, by End User
12.3.8.4 Australia
12.3.8.4.1 Overview
12.3.8.4.2 Australia Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.3.8.4.3 Australia Coagulation Market, by Disease Indication
12.3.8.4.4 Australia Coagulation Market, by Type
12.3.8.4.4.1 Australia Coagulation Market, by Clinical Laboratory Analyzer
12.3.8.4.5 Australia Coagulation Market, by Offering
12.3.8.4.5.1 Australia Coagulation Market, by Diagnosis
12.3.8.4.5.2 Australia Coagulation Market, by Treatment
12.3.8.4.6 Australia Coagulation Market, by Technology
12.3.8.4.7 Australia Coagulation Market, by End User
12.3.8.5 South Korea
12.3.8.5.1 Overview
12.3.8.5.2 South Korea Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.3.8.5.3 South Korea Coagulation Market, by Disease Indication
12.3.8.5.4 South Korea Coagulation Market, by Type
12.3.8.5.4.1 South Korea Coagulation Market, by Clinical Laboratory Analyzer
12.3.8.5.5 South Korea Coagulation Market, by Offering
12.3.8.5.5.1 South Korea Coagulation Market, by Diagnosis
12.3.8.5.5.2 South Korea Coagulation Market, by Treatment
12.3.8.5.6 South Korea Coagulation Market, by Technology
12.3.8.5.7 South Korea Coagulation Market, by End User
12.3.8.6 Rest of Asia Pacific
12.3.8.6.1 Overview
12.3.8.6.2 Rest of Asia Pacific Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.3.8.6.3 Rest of Asia Pacific Coagulation Market, by Disease Indication
12.3.8.6.4 Rest of Asia Pacific Coagulation Market, by Type
12.3.8.6.4.1 Rest of Asia Pacific Coagulation Market, by Clinical Laboratory Analyzer
12.3.8.6.5 Rest of Asia Pacific Coagulation Market, by Offering
12.3.8.6.5.1 Rest of Asia Pacific Coagulation Market, by Diagnosis
12.3.8.6.5.2 Rest of Asia Pacific Coagulation Market, by Treatment
12.3.8.6.6 Rest of Asia Pacific Coagulation Market, by Technology
12.3.8.6.7 Rest of Asia Pacific Coagulation Market, by End User
12.4 Middle East & Africa Coagulation Market, Revenue and Forecast to 2030
12.4.1 Overview
12.4.2 Middle East & Africa Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.4.3 Middle East & Africa Coagulation Market, by Disease Indication
12.4.4 Middle East & Africa Coagulation Market, by Type
12.4.4.1 Middle East & Africa Coagulation Market, by Clinical Laboratory Analyzer
12.4.5 Middle East & Africa Coagulation Market, by Offering
12.4.5.1 Middle East & Africa Coagulation Market, by Diagnosis
12.4.5.2 Middle East & Africa Coagulation Market, by Treatment
12.4.6 Middle East & Africa Coagulation Market, by Technology
12.4.7 Middle East & Africa Coagulation Market, by End User
12.4.7.1 Middle East & Africa Coagulation Market by Country
12.4.7.2 Saudi Arabia
12.4.7.2.1 Overview
12.4.7.2.2 Saudi Arabia Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.4.7.2.3 Saudi Arabia Coagulation Market, by Disease Indication
12.4.7.2.4 Saudi Arabia Coagulation Market, by Type
12.4.7.2.4.1 Saudi Arabia Coagulation Market, by Clinical Laboratory Analyzer
12.4.7.2.5 Saudi Arabia Coagulation Market, by Offering
12.4.7.2.5.1 Saudi Arabia Coagulation Market, by Diagnosis
12.4.7.2.5.2 Saudi Arabia Coagulation Market, by Treatment
12.4.7.2.6 Saudi Arabia Coagulation Market, by Technology
12.4.7.2.7 Saudi Arabia Coagulation Market, by End User
12.4.7.3 South Africa
12.4.7.3.1 Overview
12.4.7.3.2 South Africa Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.4.7.3.3 South Africa Coagulation Market, by Disease Indication
12.4.7.3.4 South Africa Coagulation Market, by Type
12.4.7.3.4.1 South Africa Coagulation Market, by Clinical Laboratory Analyzer
12.4.7.3.5 South Africa Coagulation Market, by Offering
12.4.7.3.5.1 South Africa Coagulation Market, by Diagnosis
12.4.7.3.5.2 South Africa Coagulation Market, by Treatment
12.4.7.3.6 South Africa Coagulation Market, by Technology
12.4.7.3.7 South Africa Coagulation Market, by End User
12.4.7.4 UAE
12.4.7.4.1 Overview
12.4.7.4.2 UAE Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.4.7.4.3 UAE Coagulation Market, by Disease Indication
12.4.7.4.4 UAE Coagulation Market, by Type
12.4.7.4.4.1 UAE Coagulation Market, by Clinical Laboratory Analyzer
12.4.7.4.5 UAE Coagulation Market, by Offering
12.4.7.4.5.1 UAE Coagulation Market, by Diagnosis
12.4.7.4.5.2 UAE Coagulation Market, by Treatment
12.4.7.4.6 UAE Coagulation Market, by Technology
12.4.7.4.7 UAE Coagulation Market, by End User
12.4.7.5 Rest of Middle East & Africa
12.4.7.5.1 Overview
12.4.7.5.2 Rest of Middle East & Africa Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.4.7.5.3 Rest of Middle East & Africa Coagulation Market, by Disease Indication
12.4.7.5.4 Rest of Middle East & Africa Coagulation Market, by Type
12.4.7.5.4.1 Rest of Middle East & Africa Coagulation Market, by Clinical Laboratory Analyzer
12.4.7.5.5 Rest of Middle East & Africa Coagulation Market, by Offering
12.4.7.5.5.1 Rest of Middle East & Africa Coagulation Market, by Diagnosis
12.4.7.5.5.2 Rest of Middle East & Africa Coagulation Market, by Treatment
12.4.7.5.6 Rest of Middle East & Africa Coagulation Market, by Technology
12.4.7.5.7 Rest of Middle East & Africa Coagulation Market, by End User
12.5 South & Central America Coagulation Market, Revenue and Forecast to 2030
12.5.1 Overview
12.5.2 South & Central America Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.5.3 South & Central America Coagulation Market, by Disease Indication
12.5.4 South & Central America Coagulation Market, by Type
12.5.4.1 South & Central America Coagulation Market, by Clinical Laboratory Analyzer
12.5.5 South & Central America Coagulation Market, by Offering
12.5.5.1 South & Central America Coagulation Market, by Diagnosis
12.5.5.2 South & Central America Coagulation Market, by Treatment
12.5.6 South & Central America Coagulation Market, by Technology
12.5.7 South & Central America Coagulation Market, by End User
12.5.8 South & Central America Coagulation Market by Country
12.5.8.1 Brazil
12.5.8.1.1 Overview
12.5.8.1.2 Brazil Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.5.8.1.3 Brazil Coagulation Market, by Disease Indication
12.5.8.1.4 Brazil Coagulation Market, by Type
12.5.8.1.4.1 Brazil Coagulation Market, by Clinical Laboratory Analyzer
12.5.8.1.5 Brazil Coagulation Market, by Offering
12.5.8.1.5.1 Brazil Coagulation Market, by Diagnosis
12.5.8.1.5.2 Brazil Coagulation Market, by Treatment
12.5.8.1.6 Brazil Coagulation Market, by Technology
12.5.8.1.7 Brazil Coagulation Market, by End User
12.5.8.2 Argentina
12.5.8.2.1 Overview
12.5.8.2.2 Argentina Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.5.8.2.3 Argentina Coagulation Market, by Disease Indication
12.5.8.2.4 Argentina Coagulation Market, by Type
12.5.8.2.4.1 Argentina Coagulation Market, by Clinical Laboratory Analyzer
12.5.8.2.5 Argentina Coagulation Market, by Offering
12.5.8.2.5.1 Argentina Coagulation Market, by Diagnosis
12.5.8.2.5.2 Argentina Coagulation Market, by Treatment
12.5.8.2.6 Argentina Coagulation Market, by Technology
12.5.8.2.7 Argentina Coagulation Market, by End User
12.5.8.3 Rest of South & Central America
12.5.8.3.1 Overview
12.5.8.3.2 Rest of South & Central America Coagulation Market Revenue and Forecast to 2030 (US$ million)
12.5.8.3.3 Rest of South & Central America Coagulation Market, by Disease Indication
12.5.8.3.4 Rest of South & Central America Coagulation Market, by Type
12.5.8.3.4.1 Rest of South & Central America Coagulation Market, by Clinical Laboratory Analyzer
12.5.8.3.5 Rest of South & Central America Coagulation Market, by Offering
12.5.8.3.5.1 Rest of South & Central America Coagulation Market, by Diagnosis
12.5.8.3.5.2 Rest of South & Central America Coagulation Market, by Treatment
12.5.8.3.6 Rest of South & Central America Coagulation Market, by Technology
12.5.8.3.7 Rest of South & Central America Coagulation Market, by End User
13. Coagulation Market–Industry Landscape
13.1 Overview
13.2 Growth Strategies in the Coagulation Market
13.3 Inorganic Growth Strategies
13.3.1 Overview
13.4 Organic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Siemens Healthineers AG
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Diagnostica Stago, Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 ImproGen Diagnostik Kimya San. & Tic. Ltd.?ti.
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Nordic Biomarker AB
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Sysmex Corp
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Helena Laboratories Corporation
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 F. Hoffmann-La Roche Ltd
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Genrui Biotech Co., Ltd.
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Transasia Bio-Medicals Ltd
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Horiba Ltd.
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About Us
15.2 Glossary of Terms

ページTOPに戻る

Table of Contents

Summary

The coagulation market is expected to grow from US$ 6.295 billion in 2022 to US$ 10.853 billion by 2030; it is anticipated to record a CAGR of 7.0% from 2022 to 2030.

Changing lifestyle habits and a growing geriatric population are among the major factors increasing the prevalence of blood disorders. Therefore, there is a growing demand for early diagnosis and treatment. Key players are taking several initiatives through various organic and inorganic strategies to enhance the quality of life of patient population.

• In July 2020, Sysmex Corporation launched the Automated Blood Coagulation Analyzers CN-6500/CN-3500 in Japan. The analyzer measures blood coagulation and platelet aggregation parameters, as well as thrombosis and hemostasis parameters.

• In April 2020, US-based Haemonetics Corporation acquired Enicor, a blood coagulation diagnostic system developer.

• In October 2021, Trivitron Healthcare launched a new line of coagulation analyzer products manufactured by Diagon Ltd in India.

• In June 2021, Trivitron Healthcare introduced NANO H5 and NANO H110, which help in monitoring diabetes, hemoglobin variations, and thalassemia.

• In February 2021, Siemens Healthineers and Sysmex Corporation renewed their agreement to supply, distribute, sell, and service hemostasis products across the world. The agreement also included an extension for multiple years. Further, Siemens Healthineers agreed to distribute Sysmex's automated blood coagulation analyzer, such as the CN-3000 and CN-6000.

• In July 2022, HORIBA Medical launched the latest Yumizen G800 and G1550 hemostasis analyzers, as well as a range of convenient ready-to-use reagents for common blood coagulation tests. With this expansion of its product line, HORIBA Medical now offers a comprehensive selection of hemostasis systems and advanced reagents for laboratories of all sizes and requirements.

Thus, the adoption of various organic and inorganic strategies by the key market players is expected to provide opportunities for the coagulation market growth during the forecast period.

Rising Prevalence of Cardiovascular Diseases drives the growth the Coagulation Market

Heart disease is one of the leading causes of hospitalization, death, and reduced physical performance due to conditions such as atrial fibrillation and stroke. It affects the hemostatic system, vascular system, and fluid dynamics of blood and causes arterial and venous thrombosis. Thrombosis is the leading cause of death and complications from cardiovascular disease. Blood vessels damaged by smoking and high blood pressure form cholesterol-rich plaques lining the blood vessels, which can rupture and cause platelets to clot. With coagulation disorders, there is a risk of myocardial infarction, stroke, and atherothrombotic events in the vascular beds. Heart failure (HF) is related to an increased risk of thromboembolism independent of the presence of atrial fibrillation (AF). Platelet activation and coagulation system abnormalities can increase the risk of serious thromboembolic events in patients suffering from HF.

According to the 2022 Heart Disease & Stroke Statistical Update Fact Sheet, ~119.1 million deaths due to CVDs and around 89.1 million and 68.2 million stroke and ischemic stroke cases, respectively, are recorded across the world in 2020. Per the National Center for Chronic Disease Prevention and Health Promotion, in 2023, the US reports ~877,500 deaths due to heart diseases every year. According to the American Heart Association, more than 130 million Americans are likely to acquire some form of CVD by 2035. As per ‘Global Burden of Disease Study 2019,’ CVDs were the leading cause of deaths in Asia Pacific in 2019, causing 10.8 million or 35% of the total fatalities.

A coagulation test helps prevent potential heart attack-causing blood clotting. A coagulation analyzer is used during coronary artery bypass surgery and angioplasty to monitor information on blood clotting status. Thus, the growing incidence of cardiovascular diseases bolsters the coagulation market growth.

The coagulation market is segmented on the basis of disease indication, type, offering, technology, end user, and geography. Based on disease indication, the coagulation market is segmented into vitamin K deficiency, liver disease, disseminated intravascular coagulation & pulmonary embolism, circulating anticoagulant development, hemophilia, von Willebrand's disease, and others. Based on type, the coagulation market is segmented into clinical laboratory analyzers and point-of-care testing analyzers. Clinical laboratory analyzers consist of controls & calibrators, assays & reagents, instruments/systems, coagulation factors, and others. Based on offering, the coagulation market is segmented into diagnosis and treatment. The diagnosis segment is further classified into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, D-dimmer testing, platelets function testing, and others. The treatment segment is further classified into anti-fibrinolytic drugs, birth control pills, desmopressin & immunosuppressive medicines, vitamin K supplements, blood thinners, thrombin inhibitors or thrombolytics, replacement therapies, catheter-assisted thrombus removal, and others. Based on technology, the coagulation market is segmented into optical technology, mechanical technology, electrochemical technology, and others. Based on end user, the coagulation market is segmented into clinical laboratories, hospitals, and others.

Based on geography, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share of the coagulation market. North America accounts for a significant market share owing to the growing incidences of blood disorders, increasing occurrence of cardiovascular diseases such as atrial fibrillation (AFib), and the presence of major market players engaged in new and existing product developments. The US holds the largest share of the coagulation market in North America. The burgeoning cases of blood disorders, growing prevalence of cardiovascular diseases, and government support for preventing blood disorders are anticipated to boost the North America coagulation market growth during the forecast period. As per the Canadian Task Force on Preventive Health Care, the incidence of AFib in Canada increases by 4.5% per year, with a lifetime risk of ~25% among people aged more than 40 years. Approximately 300,000 Canadians carry an inherited bleeding disorder gene. 1 in 10 of these people—at least 30,000 Canadians—have symptoms severe enough to require medical care. Many of them have not been properly diagnosed. Only 10,000 people with inherited bleeding disorders are registered in the Canadian network of comprehensive care clinics for inherited bleeding disorders. According to the Canadian Hemophilia Society, ~300,000 Canadians carry a gene for an inherited blood disorder. Thus, the rising number of cases of congenital blood disorders can be associated with the growth of the coagulation market in Canada.

American Heart Association (AHA), Centers for Disease Control and Prevention (CDC), European Union, and Canadian Task Force on Preventive Health Care are a few key primary and secondary sources referred to while preparing the report on the coagulation market.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（その他）の最新刊レポート

The Insight Partners 社の最新刊レポート

本レポートと同じKEY WORD（activated）の最新刊レポート

よくあるご質問

The Insight Partners社はどのような調査会社ですか?

The Insight Partnersはインドに本社を置く調査会社です。経験豊富な専門家チームを通じて、お客様に最適な調査と分析を提供することに専念しています。幅広い分野をカバーしていますがヘルスケ... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（その他）の最新刊レポート

The Insight Partners 社の最新刊レポート

本レポートと同じKEY WORD（activated）の最新刊レポート

よくあるご質問

The Insight Partners社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?